AI Summary & Key Takeaways
AI InsightIn the fi rst year, the mean number of injections was 5.9±1.2 whereas in the second year it was 2.1±0.9.Conclusion: These long-term real-life results suggest that the intravitreal afl ibercept is an effective treatment regimen for eyes with macular edema in BRVO.
📌 3 Key Takeaways
Özet
Purpose: To investigate the two-year visual and anatomical outcomes of patients who had intravitreal afl ibercept monotherapy for macular edema due to branch retinal vein occlusion (BRVO). Methods: Twenty-nine eyes were included in this retrospective cohort study. All eyes were newly diagnosed as BRVO and were treated with intravitreal injections of afl ibercept. After three-months loading doses, patients were treated with a single dose of afl ibercepts if needed. The best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were recorded at each monthly visit. Results: The mean ages of patients were 61.3±7.6 years. The mean BCVA was 52.2±8.5 letters at baseline, 70.1±11.2 letters at the fi rst year (p<0.001), 69.7±12.5 letters at the second year (p<0.001). The mean CMT was 555±102 μm at baseline; 285±50 μm at the fi rst year (p<0.001), 270±52 μm at the second year (p<0.001). In the fi rst year, the mean number of injections was 5.9±1.2 whereas in the second year it was 2.1±0.9.Conclusion: These long-term real-life results suggest that the intravitreal afl ibercept is an effective treatment regimen for eyes with macular edema in BRVO.